Skip to main content

Table 5 Patient data and tumor characteristics, twelve patients treated with T or T + A implants diagnosed with invasive breast cancer March 2008–March 2018 within 240 days of receiving therapy

From: Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study

Patient

Age at 1st TT Y

Age at IBC dx. Y

BMI 1st TT

Meno Status 1st TT

Prior E use

Detection

N days Last insert prior to dx

IBC (Stage) Type

Receptor status

Continued TT post dx

1

46.2

49.3

19.2

TAH FSH 4.6

Y

Mammo

206 d

T1b, N0 (1) Gd 2 IDC

ER+, PR+ Her 2 -

 

2

55.0

59.2

33.3

Post

Y

Palpable

123 d

T3, N2 (3) Gd 3 IDC

ER-, PR-Her 2 -

 

3

50.0

52.9

19.2

Pre

OCP Current

Mammo

34 d

T1c, N0 (1) Gd 1 IDC

ER+, PR+ Her 2 -

T + AI x 5y T alone

4

67.6

70.2

24.7

TAH BSO

Y

Mammo

151 d

T1b, N0 (1) Gd 1 IDC

ER+, PR+ Her 2 –

 

5

44.9

48.5

21.5

TAH

N

Mammo

48 da

T1c, N0 (1) Gd 1, IDC

ER+, PR- Her 2 -

 

6

48.9

55.5

24.4

TAH

Y

Mammo

146 d

T1b, N1a (2) Gd 2 ILC

ER+, PR- Her 2 -

 

7

56.2

60.6

28.8

TAH BSO

Y

Mammo

51 d

T1 N0 (1) Gd 2 IDC

ER+, PR+ Her 2 -

 

8

50.0

55.2

28.7

Post

N

Mammo

54 d

T1a N0 (1) 1.2 mm IDC

ER-, PR+ Her 2 -

T alone

9

58.0

61.5

39.3

TAH BSO

N

Palpable

50 d

T2 N1 (2) Gd 3 IDC

ER+ PR+ Her 2 -

T + AI Note: tested BRCA 2 pos.

10

39.7

43.4

23.2

Pre

N

Palpable

15 d

T1c N0 (1) Gd 2 IDC

ER+ PR+ Her 2-

 

11

44.0

51.0

23.5

Pre

N

Mammo

92 d

Clinical T2 N0 (2A) Gd 3 IDC

ER+ PR+ Her 2 +

T + AI

  1. aPatient was diagnosed 48 d after a single pellet insertion following a 23-month lapse in therapy
  2. Abbr: TT testosterone therapy, IBC (invasive breast cancer), Dx. (diagnosis), BMI (Body mass index), E2 (estradiol), OCP (Oral Contraceptive Pill), IDC (Infiltrating ductal carcinoma), ILC (infiltrating lobular carcinoma), T (tumor size), a (< 0.5 cm), b (> 0.5, < 1 cm), c (> 1, < 2 cm), T2 (20mm–50mm), T3 (> 50 mm), N (node status); N0 (no nodes positive), N1a (Single node < 5 mm), N2 (4–9 nodes positive), Gd (tumor grade: 1 low grade, 2 intermediate grade, 3 high grade), ER (estrogen receptor), PR (progesterone receptor), HER2 (human epidermal growth factor 2), T (testosterone implant), T + AI (testosterone combined with an aromatase inhibitor implant), Mammo (mammography)